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PCR-SSPPromising studies suggest that defects in synaptic plasticity detected in schizophrenia may be linked to
neurodevelopmental and neurodegenerative abnormalities and contribute to disease-associated cognitive
impairment. We aimed to clarify the role of the synaptic plasticity regulatory proteins, nerve growth factor
(NGF) and its receptor (NGFR) in the pathogenesis of schizophrenia by comparative analysis of their blood levels
and functional single nucleotide polymorphisms (SNPs) in genes encoding these proteins (NGF and NGFR) in
schizophrenia-affected and healthy subjects. Relationships between the selected SNPs' genotypes and NGF and
NGFR plasma levels were also assessed. Our results demonstrated a positive association between schizophrenia
and the NGF rs6330 as well as the NGFR rs11466155 and rs2072446 SNPs. Also, a negative association between
this disorder and NGF rs4839435 as well as NGFR rs734194 was found. In both, haloperidol-treated and
antipsychotic-free patients decreased blood levels of the NGF and NGFR were found, and a positive interrelation
between rs6330 and rs2072446 carriage and decreased NGF and NGFR levels, respectively, was revealed. In con-
clusion, our results demonstrate association of schizophrenia with the rs6330, rs4839435 and rs734194,
rs11466155, rs2072446 as well as with the decreased blood levels of corresponding proteins. Our ﬁndings indi-
cate the implication of alterations in NGFR and NGFR genes in schizophrenia, particularly, in defects of synaptic
plasticity. Furthermore, the data obtained suggests that at least in Armenian population the NGF rs6330*T and
NGFR rs11466155*T, rs2072446*T alleles might be nominated as risk factors, whereas the NGF rs4839435*A
and NGFR rs734194*G alleles might be protective against developing schizophrenia.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Schizophrenia is a chronic, severe, and disabling mental disorder
with a high heritability (approximately 80%) [1,2]. This complex disor-
der with still unclear etiology and molecular pathomechanisms is char-
acterized by both neurodevelopmental [3] and neurodegenerative
abnormalities [4–6] and cognitive impairments [7] linked to behavioral
changes [8].
Promising studies suggest that defects in synaptic plasticity detected
in schizophrenia [9]may be linked to neurodevelopmental and neurode-
generative abnormalities [10–13] and contribute to cognitive impair-
ment associated with this disease [14–17]. Therefore, study of synaptic
plasticity regulatory genes in schizophrenia represents a special interest,
as it can provide insight into molecular mechanisms of schizophrenia-
associated cognitive dysfunction and sufﬁciently contribute to develop-
ment of target-oriented therapy for this disorder. Here, genes encoding74 10281540.
an), s_atshemyan@mb.sci.am
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. This is an open access article underneurotrophinsmight be considered as themost attractive candidates, be-
cause these proteins and their receptors are expressed in the neuronal
populations of the brain undergoing synaptic plasticity and also partici-
pate in neuronal development, synaptogenesis, and response to stress/
anxious stimuli [18]. In addition, neurotrophins play an important role
in the immune response [19], which is upregulated in schizophrenia
[20,21].
In our recent study we demonstrated implication of genetic varia-
tion of brain-derived neurotropic factor, modulators of brain plasticity
in cognitive processes [15], in pathogenesis of schizophrenia [12].
Other importantmembers of neurotrophin family are nerve growth fac-
tor (NGF) and its receptor (NGFR), the essential mediators of synaptic
and morphological plasticity, neuronal growth, survival, and differenti-
ation, especially in the developing brain [18,22]. The mature form of
nerve growth factor (NGF) derives from a precursor, proNGF, which
was recently discovered to exert crucial brain functions responsible
for mood and cognitive activities [23]. Jockers-Scherubl et al. reported
that in generalized anxiety disorder the NGF serum level increases in
response to positive environments, namely, after successful cognitive
behavioral therapy [24]. Moreover, decreased blood levels of NGF
among ﬁrst-episode schizophrenia patients compared to healthy sub-
jects have been observed [25,26]. Interestingly, it has been shown thatthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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patients with schizophrenia compared to healthy control subjects [27].
The potential implication of NGFR in schizophrenia either at protein or
genetic levels has not been studied yet.
This study was aimed to clarify the role of the NGF and NGFR
proteins in the pathogenesis of schizophrenia by comparative analy-
sis of their blood levels and functional single nucleotide polymor-
phisms (SNPs) in genes encoding these proteins (NGF and NGFR) in
schizophrenia-affected and healthy subjects. Relationships between
the selected SNPs' genotypes and NGF and NGFR plasma levels were
also assessed.Table 1
Primer nucleotide sequences for NGF and NGFR genes for PCR-SSP.2. Materials and methods
2.1. Study population
A total of 475 unrelated Caucasian individuals of Armenian national-
ity living in Armenia (200 chronic schizophrenia patients, 25 ﬁrst-
episode schizophrenia patients and 250 healthy subjects) were enrolled
in this study. All chronic patients (female/male: 62/138, mean age± SD:
42.4±8.2 years, age at the ﬁrst-onset of disease: 25.2±9.1 years, dura-
tion of disease: 17.2 ± 7.2 years, patients with/without family history of
psychiatric disorders: 84/116) and ﬁrst-episode patients (female/male:
12/13, mean age ± SD: 25.3 ± 9.2 years, patients with/without family
history of psychiatric disorders: 10/15) were recruited from clinics of
the Psychiatric Medical CenterMH RA. Theywere diagnosed as paranoid
schizophrenics (ICD-10 code: F20.0, DSM-IV-TR code: 295.30 [28,29]) by
two independent experienced psychiatrists according to the presence of
the relevant symptoms and the results of the Structured Clinical Inter-
view for DSM-IV-TR [29]. Chronic patients were treatedwith haloperidol
and ﬁrst-episode patients were antipsychotic-free. Age- and sex-
matched healthy volunteers (female/male: 77/173, mean age ± SD:
43.6 ± 9.1 years) were recruited among the staff and blood donors of
the Erebouni Medical Center MH RA and served as a reference control
population (controls). They passed a special examination by two inde-
pendent experienced psychiatrists to establish no personal or family
history of mental disorders. Any medical condition or treatment known
to affect the brain, or meeting DSM-IV criteria for mental retardation as
determined from the non-patient version of the Structured Clinical
Interview for DSM-IV-TR Axis I Disorders [30]. Also, the healthy subjects
were free of anymedication for at least 1 month prior to blood sampling.
Exclusion criteria for all study participants included any serious neuro-
logical, endocrine or metabolic disorder, acute or chronic infections, au-
toimmune, inﬂammatory or autoinﬂammatory diseases, malignancies,
and any surgical interventions within the previous 12 months. Fifty-
two schizophrenia-affected subjects and sixty-seven healthy subjects
were nicotine-dependent (tobacco cigarette smokers).
All subjects gave their informed consents to provide 10ml of venous
blood for the purposes of this study. The study was approved by the
Ethical Committee of the Institute of Molecular Biology of the National







NGFR, rs734194 5′-GCT-GGA-GCT-GGC-GTC-TGT-CT-3′2.2. Collection of blood samples and separation of plasma
10 ml of the morning fasting venous blood was collected from each
study subject using EDTA as anticoagulant. The plasma was isolated by








5′-AGC-AGC-CAG-GAT-GGA-GCA-AT-3′2.3. Genomic DNA extraction
Genomic DNA was isolated from the fresh blood samples according
to the standard phenol–chloroform method [31] and stored at−30 °C
until further use.2.4. Selection of SNPs for NGF and NGFR genes
In total, ﬁve SNPs within the NGF and NGFR genes were selected
based on either their functionality according to the National Center of
Biotechnology Information (NCBI) databases [http://www.ncbi.nlm.
nih.gov/] or tagging results obtained using the International HapMap
Project database [32].2.5. Genotyping of NGF and NGF SNPs
DNA samples of all patients with chronic schizophrenia and controls
were genotyped for NGF rs6330, rs4839435 and NGFR rs734194,
rs11466155, rs2072446 SNPs using polymerase chain reaction with
sequence-speciﬁc primers (PCR-SSP) [33]. The sequences of speciﬁc
primers were designed based on relevant DNA sequences available in
the NCBI GenBank database (http://www.ncbi.nlm.nih.gov/genbank/;
Gene IDs: 4803, 4804). Nucleotide sequences of the primers used for
genotyping of the NGF and NGFR SNPs are presented in Table 1.
The presence/absence of allele-speciﬁc amplicons was visualized by
electrophoresis in 2% agarose gel stained with ethidium bromide ﬂuo-
rescent dye. To check the reproducibility of results, randomly selected
DNA samples of study subjects (10% of total) were genotyped twice.2.6. Determination of the NGF and NGFR levels in the blood plasma
The levels of the NGF and NGFR proteins in the blood plasma
samples of study subjects were measured with a solid-phase enzyme-
linked immunosorbent assay (ELISA) using commercial kits (Human
NGF/NGFR ELISA kit, Boster Biological Technology Co., Inc., USA and
Human NGFR ELISA kit, RayBiotech, Inc., USA) according to manufac-
turers' instructions. Each sample, standard, and blank control (zero
standard) were run in duplicates on the same microplate. Also, dupli-
cates of the same cases and controls (three of each) were run in each
assay/on each microplate. The calculated overall intra-assay coefﬁcient
of variation (CV) was 5%, and the calculated overall inter-assay coefﬁ-
cient of variation was 8%. Standard curves were reproducible with CV
b 4%. Detection limit of the NGF (beta subunit) and NGFR assays was
1 pg/ml and 80 pg/ml, respectively. Concentration of proteins was
expressed in pg/ml of plasma.
From 200 chronic patients with schizophrenia and 250 controls
enrolled in the genotyping experiments a total of 240 plasma samples
(120 of patients and 120 of controls) were subjected to ELISA. Addition-
ally, in order to check the effect of antipsychotic treatment, plasma sam-
ples of a small group of antipsychotic-naive ﬁrst-episode schizophrenia
patients were also analyzed.
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Distributions of genotypes for investigated SNPs were checked for
correspondence to the Hardy–Weinberg equilibrium (H–W). To reveal
a potential association of these SNPswith schizophrenia, their genotype,
allele (gene) and phenotype frequencies (carriage rates) in patients and
controls were compared. The signiﬁcance of differences between allele
and phenotype frequencies in study groups was determined using
Pearson's chi-square test. The odds ratio (OR), 95% conﬁdence interval
(CI), and Pearson's p-value were calculated. p-Values were adjusted
by Bonferroni multiple correction approach [34], and those less than
0.05 were considered statistically signiﬁcant. Statistical power of the
present study was estimated according to the earlier described protocol
[35]. Overall descriptive statistics and the Mann–Whitney U test were
used for evaluation of intergroup differences in the blood plasma levels
of theNGF andNGFR proteins. Group statistics, otherwise speciﬁed, was
presented as median [interquartile range]. p-Values less than 0.05 were
considered signiﬁcant. The data were evaluated using GraphPad Prism
3.03 software (GraphPad Software Inc., USA).
3. Results
3.1. Distribution of the NGF rs6330, rs4839435 and NGFR rs734194,
rs11466155, rs2072446 polymorphisms in patients with schizophrenia
and controls
Distribution of NGF rs6330, rs4839435 and NGFR rs734194,
rs11466155, rs2072446 alleles and genotypes in the groups of schizo-
phrenia patients and healthy subjects were in compliance with H–W
equilibrium. Statistical power of the present study, the difference in
the carriage of the rs6330*T and rs4839435*A alleles of the NGF gene
and rs734194*G, rs11466155*T, rs2072446*T alleles of the NGFR gene
between the patients and healthy subjects, reached 99.8%, 100%, and
94.7%, 95.9%, 99,2%, respectively.
The allele and phenotype frequencies of the studied genetic variant
in schizophrenia-affected and healthy subjects are shown in Table 2.
According to the data obtained, the rs6330*T allele of the NGF gene
was more frequent in patients than in controls (patients vs. controls,
0.34 vs. 0.20, pnominal = 4.0E−6, OR = 2.01, 95%CI: 1.24–1.66). Also,
the carriers of rs6330*T minor allele were overrepresented in the
group of patients compared to controls (0.57 vs. 0.35, pnominal =
3.0E−6, OR = 2.48, 95%CI: 1.33–2.03). In contrast, the rs4839435*ATable 2
Distribution of genotypes, alleles and carriage ofmutant alleles ofNGF rs6330, rs4839435 andNG
and controls (n = 250). The data are presented as absolute numbers with proportions (%) in p
Gene, SNP Genotypes
NGF rs6330 CC CT TT
SCZ 86 (0.43) 92 (0.46) 22
Controls 163 (0.65) 72 (0.29) 15
p
NGF rs4839435 GG GA AA
SCZ 125 (0.63) 62 (0.31) 13
Controls 106 (0.42) 121 (0.48) 23
p
NGFR rs734194 TT TG GG
SCZ 139 (0.70) 53 (0.27) 8 (0
Controls 136 (0.54) 92 (0.37) 22
p
NGFR rs11466155 CC CT TT
SCZ 79 (0.40) 88 (0.44) 33
Controls 137 (0.55) 94 (0.38) 19
p
NGFR rs2072446 CC CT TT
SCZ 68 (0.34) 106 (0.53) 26
Controls 132 (0.56) 91 (0.33) 27
p
a pnominal values for comparison of minor allele frequency between SCZ and controls.
b pnominal values for comparison of minor allele carriage between SCZ and controls.minor allele of the NGF gene was more frequent among controls com-
pared to patients (0.33 vs. 0.22, pnominal = 0.00016, OR = 0.56, 95%CI:
0.59–0.86). Also, the carriers of this allele weremore in the group of con-
trols compared to patients (0.58 vs. 0.38, pnominal = 2.2E−5, OR= 0.44,
95%CI: 0.51–0.79). Further, we found that the rs11466155*T minor allele
of the NGFR gene was overrepresented in patients with schizophrenia
compared to healthy subjects (0.38 vs. 0.26, pnominal = 0.0001,
OR = 1.77, 95%CI: 1.16–1.55). Also, the carriers of the rs11466155*T
minor allele (CT+TT) were more frequent in patients than in controls
(0.61 vs. 0.45, pnominal = 0.0012, OR = 1.86, 95%CI: 1.14–1.75). On the
contrary, the frequency (0.27 vs. 0.17, pnominal = 0.0004, OR = 0.56,
95%CI: 0.57–0.87) and carriers (0.46 vs. 0.31, pnominal = 0.0011,
OR = 0.52, 95%CI: 0.55–0.87) of the rs734194*G allele of NGFR gene
were higher in controls than in schizophrenia-affected subjects. The
NGFR rs2072446*T minor allele frequency again was higher in patients
than in controls (0.39 vs. 0.29, pnominal = 0.0009, OR = 1.59, 95%CI:
1.13–1.64). The same applies to the carriers of the NGFR rs2072446*T
allele (0.66 vs. 0.47, pnominal = 6.7E−05, OR = 2.17, 95%CI: 1.24–1.95).
After Bonferroni correction for the number of tested loci (n = 5), differ-
ence in allele frequency between the patient and control groups for the
rs6330*T: (pcorrected = 2.00E−05), rs4839435*A (pcorrected = 0.0008),
rs11466155*T (pcorrected = 0.006), rs734194*G (pcorrected = 0.006), and
rs2072446*T (pcorrected = 0.005) minor alleles remained signiﬁcant.
3.2. Levels of the NGF and NGFR proteins in the blood plasma
The NGF and NGFR plasma levels in 120 haloperidol-treated, 25
antipsychotic-free schizophrenia patients and 120 controls were
compared.
According to the data obtained, reduced median levels of NGF in
haloperidol-treated patients compared to controls were detected
(patients vs. controls: 4.21 [4.1, 5.67] pg/ml vs. 7.01 [6.89, 7.14] pg/ml,
p b 0.0001). The NGF median levels in antipsychotic-free patients
were also lower compared to controls (patients vs. controls: 4.66
[3.79, 4.73] pg/ml vs. 7.01 [6.89, 7.14] pg/ml, p b 0.0001), while no sig-
niﬁcant difference in this parameter between two groups of patients
was found (p = 0.96).
Concerning NGFR, haloperidol-treated patients with schizophrenia
had signiﬁcantly lower median levels of this protein than controls
(patients vs. controls: 624.2 [617.4, 631.2] pg/ml vs. 636.8 [628.3,
640.0] pg/ml, p b 0.0001). The same applies to antipsychotic-free
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C T T
(0.16) 246 (0.62) 154 (0.38) 121 (0.61)
(0.07) 368 (0.74) 132 (0.26) 113 (0.45)
0.0001a 0.0012b
C T T
(0.13) 242 (0.61) 158 (0.39) 132 (0.66)
(0.11) 355 (0.89) 145 (0.29) 118 (0.47)
0.0009a 6.7E−05b
Fig. 2. The NGFR protein plasma levels [median (interquartile range)] in patients with
schizophrenia (SCZ, n = 120) and controls (n= 120). The data are expressed as whisker
box plots; the box represents the 25th–75th percentiles, the median is indicated by a bar
across the box, the whiskers on each box represent the minimum and maximum levels.
27R. Zakharyan et al. / BBA Clinical 1 (2014) 24–29[628.3, 640.0] pg/ml, p b 0.0001). Also, as was detected in the case of
NGF, we found no difference in the median levels of NGFR between
schizophrenia patients non-treated and treated with antipsychotics
(non-treated patients vs. treated patients: 624.8 [615.5, 629.2] pg/ml
vs. 624.2 [617.4, 631.2] pg/ml, p = 0.79).
3.3. Relationships between the selected SNPs' genotypes of the NGF and
NGFR genes and the blood plasma levels of NGF and NGFR proteins
The relationships between the genotypes of the NGF gene rs6330
and rs4839435 SNPs and the NGF protein plasma levels as well as
between the genotypes of the NGFR gene rs734194, rs11466155 and
rs2072446 SNPs and the NGFR protein plasma levels in schizophrenia
patients and controls were evaluated.
Relevant intergroup analysis revealed signiﬁcantly higher NGF me-
dian plasma level in NGF rs6330 CC homozygotes than in rs6330*T
minor allele carriers (CT+TT) both in patients (CC vs. CT+TT: 5.63
[4.18, 5.75] pg/ml vs. 4.17 [4.09, 4.24] pg/ml, p b 0.0001) and controls
(CC vs. CT+TT: 7.05 [6.94, 7.28] pg/ml vs. 6.89 [5.66, 7.02] pg/ml,
p b 0.0001). Concerning NGFR median plasma level of this protein
was found signiﬁcantly increased in rs2072446 CC homozygotes com-
pared to rs2072446*T minor allele carriers (CT+TT) both in patients
(CC vs. CT+TT: 628 [619, 634.3] pg/ml vs. 623.6 [614.6, 628] pg/ml,
p = 0.038) and controls (CC vs. CT+TT: 639.4 [638.7, 656.2] pg/ml
vs. 628 [621.7, 631.1] pg/ml, p b 0.0001). The results are presented in
Figs. 1 and 2.
4. Discussion
The results of the present study demonstrated a positive association
between schizophrenia and the rs6330 SNP of the NGF gene as well as
the rs11466155 and rs2072446 SNPs of the NGFR gene. Also, a negative
association between this disorder and rs4839435 SNP of the NGF gene
as well as the rs734194 SNP of the NGFR gene was found. In both,
haloperidol-treated and antipsychotic-free patients with schizophrenia
decreased blood plasma levels of the NGF and NGFR proteins were
found, and a positive interrelation between carriage of theminor alleles
of the rs6330 and rs2072446 SNPs and decreased plasma levels of the
NGF and NGFR proteins, respectively, was revealed.
A non-synonymous rs6330 (104CNT) SNP of theNGF gene produces
an alanine to valine substitution at amino acid position 35, and is
thought to affect intracellular processing and secretion of the NGF pro-
tein [36], and our present study demonstrating relationship between
the rs6330 genotypes and NGF plasma levels provides further evidence
to support this suggestion. It has been also shown that the rs6330 SNP is
associated with executive dysfunction in patients with Alzheimer's dis-
ease, anxiety-related traits and affective disorders [37]. However, study
of association between schizophrenia and the rs6330 SNP of the NGF
gene has been for the ﬁrst time performed in the present study. TheFig. 1. The NGF protein plasma levels [median (interquartile range)] in patients with
schizophrenia (SCZ, n = 120) and controls (n= 120). The data are expressed as whisker
box plots; the box represents the 25th–75th percentiles, the median is indicated by a bar
across the box, the whiskers on each box represent the minimum and maximum levels.same applies to the rs4839435 SNP of the NGF gene. It has to be men-
tioned that in schizophrenia another polymorphism of the NGF gene,
the rs12760036 SNP was studied by Park et al. in Korean population.
The results of their study suggested an association of the mentioned
SNP with susceptibility to schizophrenia. Also, signiﬁcant differences in
the AG and CA haplotype frequencies within the linkage disequilibrium
block between the rs12760036 and rs4839435 SNPs between schizo-
phrenia patients and controls were found indicating the rs12760036*C
minor allele as a risk factor for schizophrenia in Koreans [38].
Concerning blood levels of NGF, our results are in agreement with
previous report of Xiong et al. that demonstrated lower blood levels
of this protein among ﬁrst-episode schizophrenia patients compared
to healthy subjects [25,26]. Increased blood levels of NGF were
found in several inﬂammatory and autoimmune states [39–41]. More-
over, in both animal and human studies a correlation between some
psychopathological conditions (diabetes mellitus, allergic diseases and
asthma) and blood levels of NGF was demonstrated [42–44].
It has been shown that both pre- and postnatal injections of NGF
lead to production ofmassive transformation of chromafﬁn cells in sym-
pathetic nerve cells of the rat adrenal medulla [45]. Moreover, Aloe and
Levi-Montalcini reported that NGF treatment after birth results in only a
partial replacement of chromafﬁn cells with nerve cells [45]. Study of
Chen et al. in newborn mice revealed the ability of NGF to prevent
destructive effects of vinblastine on sympathetic ganglia [46]. Further,
experimentswith daily treatment of newborn rats revealed that NGF in-
duces increased volume and enhanced synthesis of tyrosine hydroxy-
lase in chemically axotomized sympathetic ganglia [47]. Some earlier
studies also showed that mouse submandibular glands synthesize and
release into the saliva large quantities of NGF and that synthesis of
this protein is controlled by testosterone and thyroxine [reviewed in
48]. Later, Levi-Montalcini and Aloe found that systemicmurineNGF in-
jections lead to growth and differentiation of sensory and sympathetic
nerve cells as well as on several populations of cells in the central
nervous system of Xenopus laevis tadpoles [49]. Using animal model of
aggression Spillantini et al. detected increased NGF mRNA and protein
production in the hypothalamus [50]. Aloe et al. found that intraspeciﬁc
ﬁghting causes release of NGF from salivary gland into the bloodstream
in mice and that the amount of circulating NGF depends on the number
of ﬁghting episodes [51]. Furthermore, Alleva and Francia showed that
intermale aggression in mice, representing a psychosocial stressful con-
dition, markedly alters NGF levels both in plasma and selected brain
areas, including the hypothalamus and hippocampus [42]. Also, it was
shown that murine NGF can be used successfully for the treatment of
such human diseases as corneal and pressure ulcers [52–54], vasculite
[55], and crush syndrome [56]. Moreover, therapeutic efﬁciency of
recombinant human NGF (rhNGF) in rodent and primate models of ex-
perimental allergic Alzheimer's disease [57,58] and encephalomyelitis
[59] was demonstrated. Also, recently, an important role of NGF in em-
bryo chicken development, namely, in the regulation of somite survival
28 R. Zakharyan et al. / BBA Clinical 1 (2014) 24–29and axial rotation was detected [60]. These observation together with
our present data, suggested the potential pharmacological role of NGF
as a useful therapeutic agent in many pathological conditions.
In the case of theNGFR, our study for the ﬁrst time demonstrated as-
sociation of the NGFR gene rs2072446, rs11466155 and rs734194 SNPs
with schizophrenia as well as decreased plasma levels of this protein
in schizophrenia-affected subjects. Notably, the rs11466155 synony-
mous SNP of theNGFR genewas not studied before in any diseased con-
dition. The rs2072446 SNP of the NGFR gene leading to substitution of
serine to leucine at 205 amino acid position of the NGFR protein poly-
peptide chain and the haplotype containing rs734194 SNP in the three
prime untranslated region (3′-UTR) of this gene were recently found
to be associatedwith an increased risk of Alzheimer's disease in Chinese
[61].
5. Conclusions
In summary, our results demonstrate association of schizophrenia
with the rs6330, rs4839435 and rs734194, rs11466155, rs2072446
functional SNPs of genes encoding NGF and NGFR, respectively, as well
as with the decreased blood levels of these proteins. Our ﬁndings
indicate the implication of alterations in genes encoding NGF and its
receptor in pathogenesis of schizophrenia, particularly, in defects of
synaptic plasticity detected in this disorder. Furthermore, the data ob-
tained suggests that at least in Armenian population the rs6330*T and
rs11466155*T, rs2072446*T alleles of the NGF and NGFR genes, respec-
tively, might be nominated as risk factors for schizophrenia, whereas
theNGF rs4839435*A and theNGFR rs734194*G allelesmight be protec-
tive against developing schizophrenia.
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